Recent Advancements in Cell-Based Therapies in Melanoma
Abstract
:1. Introduction
2. TILS Therapy in Melanoma
3. Modified Cell Therapies in Melanoma
3.1. TCR-Transduced T-Cell Therapy in Melanoma
3.2. CAR T-Cell Therapy in Melanoma
3.3. NK Cell Therapy in Melanoma
4. Bi-Specific T-Cell Engagers
5. Conclusions
Author Contributions
Funding
Data Availability Statement
Conflicts of Interest
References
- Henley, S.J.; Ward, E.M.; Scott, S.; Ma, J.; Anderson, R.N.; Firth, A.U.; Thomas, C.C.; Islami, F.; Weir, H.K.; Lewis, D.R.; et al. Annual Report to the Nation on the Status of Cancer, Part I: National Cancer Statistics. Cancer 2020, 126, 2225–2249. [Google Scholar] [CrossRef] [PubMed]
- Curti, B.D.; Faries, M.B. Recent Advances in the Treatment of Melanoma. N. Engl. J. Med. 2021, 384, 2229–2240. [Google Scholar] [CrossRef] [PubMed]
- Robert, C.; Thomas, L.; Bondarenko, I.; O’Day, S.; Weber, J.; Garbe, C.; Lebbe, C.; Baurain, J.-F.; Testori, A.; Grob, J.-J.; et al. Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma. N. Engl. J. Med. 2011, 364, 2517–2526. [Google Scholar] [CrossRef] [PubMed]
- Shiravand, Y.; Khodadadi, F.; Kashani, S.M.A.; Hosseini-Fard, S.R.; Hosseini, S.; Sadeghirad, H.; Ladwa, R.; O’Byrne, K.; Kulasinghe, A. Immune Checkpoint Inhibitors in Cancer Therapy. Curr. Oncol. 2022, 29, 3044–3060. [Google Scholar] [CrossRef]
- Hodi, F.S.; Chiarion -Sileni, V.; Lewis, K.D.; Grob, J.-J.; Rutkowski, P.; Lao, C.D.; Cowey, C.L.; Schadendorf, D.; Wagstaff, J.; Dummer, R.; et al. Long-Term Survival in Advanced Melanoma for Patients Treated with Nivolumab plus Ipilimumab in CheckMate 067. J. Clin. Oncol. 2022, 40, 9522. [Google Scholar] [CrossRef]
- Jerby-Arnon, L.; Shah, P.; Cuoco, M.S.; Rodman, C.; Su, M.-J.; Melms, J.C.; Leeson, R.; Kanodia, A.; Mei, S.; Lin, J.-R.; et al. A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. Cell 2018, 175, 984–997.e24. [Google Scholar] [CrossRef]
- Brastianos, P.K.; Kim, A.E.; Giobbie-Hurder, A.; Lee, E.Q.; Lin, N.U.; Overmoyer, B.; Wen, P.Y.; Nayak, L.; Cohen, J.V.; Dietrich, J.; et al. Pembrolizumab in Brain Metastases of Diverse Histologies: Phase 2 Trial Results. Nat. Med. 2023, 29, 1728–1737. [Google Scholar] [CrossRef]
- Pires da Silva, I.; Lo, S.; Quek, C.; Gonzalez, M.; Carlino, M.S.; Long, G.V.; Menzies, A.M. Site-Specific Response Patterns, Pseudoprogression, and Acquired Resistance in Patients with Melanoma Treated with Ipilimumab Combined with Anti-PD-1 Therapy. Cancer 2020, 126, 86–97. [Google Scholar] [CrossRef]
- Hussaini, S.; Chehade, R.; Boldt, R.G.; Raphael, J.; Blanchette, P.; Maleki Vareki, S.; Fernandes, R. Association between Immune-Related Side Effects and Efficacy and Benefit of Immune Checkpoint Inhibitors—A Systematic Review and Meta-Analysis. Cancer Treat. Rev. 2021, 92, 102134. [Google Scholar] [CrossRef]
- Wang, D.Y.; Salem, J.-E.; Cohen, J.V.; Chandra, S.; Menzer, C.; Ye, F.; Zhao, S.; Das, S.; Beckermann, K.E.; Ha, L.; et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. JAMA Oncol. 2018, 4, 1721–1728. [Google Scholar] [CrossRef]
- Chen, Y.-C.; Jaffer, M.; Zhou, L.; Moslehi, J.; Forsyth, P.A.; Fecher, L.A. A Brain, A Heart, and the Courage: Balancing Benefit and Toxicity of Immunotherapy in Melanoma. Am. Soc. Clin. Oncol. Educ. Book. 2023, 43, e390594. [Google Scholar] [CrossRef] [PubMed]
- Sarnaik, A.A.; Hamid, O.; Khushalani, N.I.; Lewis, K.D.; Medina, T.; Kluger, H.M.; Thomas, S.S.; Domingo-Musibay, E.; Pavlick, A.C.; Whitman, E.D.; et al. Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. J. Clin. Oncol. 2021, 39, 2656–2666. [Google Scholar] [CrossRef] [PubMed]
- van den Berg, J.H.; Heemskerk, B.; van Rooij, N.; Gomez-Eerland, R.; Michels, S.; van Zon, M.; de Boer, R.; Bakker, N.A.M.; Jorritsma-Smit, A.; van Buuren, M.M.; et al. Tumor Infiltrating Lymphocytes (TIL) Therapy in Metastatic Melanoma: Boosting of Neoantigen-Specific T Cell Reactivity and Long-Term Follow-Up. J. Immunother. Cancer 2020, 8, e000848. [Google Scholar] [CrossRef] [PubMed]
- Lin, B.; Du, L.; Li, H.; Zhu, X.; Cui, L.; Li, X. Tumor-Infiltrating Lymphocytes: Warriors Fight against Tumors Powerfully. Biomed. Pharmacother. 2020, 132, 110873. [Google Scholar] [CrossRef] [PubMed]
- Paijens, S.T.; Vledder, A.; de Bruyn, M.; Nijman, H.W. Tumor-Infiltrating Lymphocytes in the Immunotherapy Era. Cell Mol. Immunol. 2021, 18, 842–859. [Google Scholar] [CrossRef]
- Maibach, F.; Sadozai, H.; Seyed Jafari, S.M.; Hunger, R.E.; Schenk, M. Tumor-Infiltrating Lymphocytes and Their Prognostic Value in Cutaneous Melanoma. Front. Immunol. 2020, 11, 2105. [Google Scholar] [CrossRef]
- June, C.H.; Riddell, S.R.; Schumacher, T.N. Adoptive Cellular Therapy: A Race to the Finish Line. Sci. Transl. Med. 2015, 7, 280ps7. [Google Scholar] [CrossRef]
- Rosenberg, S.A.; Spiess, P.; Lafreniere, R. A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating Lymphocytes. Science 1986, 233, 1318–1321. [Google Scholar] [CrossRef]
- Betof Warner, A.; Corrie, P.G.; Hamid, O. Tumor-Infiltrating Lymphocyte Therapy in Melanoma: Facts to the Future. Clin. Cancer Res. 2023, 29, 1835–1854. [Google Scholar] [CrossRef]
- Atkins, M.B.; Lotze, M.T.; Dutcher, J.P.; Fisher, R.I.; Weiss, G.; Margolin, K.; Abrams, J.; Sznol, M.; Parkinson, D.; Hawkins, M.; et al. High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993. J. Clin. Oncol. 1999, 17, 2105. [Google Scholar] [CrossRef]
- Chesney, J.; Lewis, K.D.; Kluger, H.; Hamid, O.; Whitman, E.; Thomas, S.; Wermke, M.; Cusnir, M.; Domingo-Musibay, E.; Phan, G.Q.; et al. Efficacy and Safety of Lifileucel, a One-Time Autologous Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy, in Patients with Advanced Melanoma after Progression on Immune Checkpoint Inhibitors and Targeted Therapies: Pooled Analysis of Consecutive Cohorts of the C-144-01 Study. J. Immunother. Cancer 2022, 10, e005755. [Google Scholar] [CrossRef] [PubMed]
- Medina, T.; Chesney, J.A.; Whitman, E.; Kluger, H.; Thomas, S.; Sarnaik, A.; Kirkwood, J.; Larkin, J.; Weber, J.S.; Hamid, O.; et al. 119O Long-Term Efficacy and Patterns of Response of Lifileucel Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy in Patients with Advanced Melanoma: A 4-Year Analysis of the C-144-01 Study. Immuno-Oncol. Technol. 2023, 20, 100591. [Google Scholar] [CrossRef]
- Rohaan, M.W.; Borch, T.H.; van den Berg, J.H.; Met, Ö.; Kessels, R.; Geukes Foppen, M.H.; Stoltenborg Granhøj, J.; Nuijen, B.; Nijenhuis, C.; Jedema, I.; et al. Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma. N. Engl. J. Med. 2022, 387, 2113–2125. [Google Scholar] [CrossRef] [PubMed]
- Khushalani, N.I.; Truong, T.-G.; Thompson, J.F. Current Challenges in Access to Melanoma Care: A Multidisciplinary Perspective. Am. Soc. Clin. Oncol. Educ. Book. 2021, 41, e295–e303. [Google Scholar] [CrossRef]
- Zippel, D.; Friedman-Eldar, O.; Rayman, S.; Hazzan, D.; Nissan, A.; Schtrechman, G.; Markel, G.; Schachter, J.; Itzhaki, O.; Besser, M.J. Tissue Harvesting for Adoptive Tumor Infiltrating Lymphocyte Therapy in Metastatic Melanoma. Anticancer Res. 2019, 39, 4995–5001. [Google Scholar] [CrossRef]
- Larkin, J.; Sarnaik, A.; Chesney, J.A.; Khushalani, N.I.; Kirkwood, J.M.; Weber, J.S.; Lewis, K.D.; Medina, T.M.; Kluger, H.M.; Thomas, S.S.; et al. Lifileucel (LN-144), a Cryopreserved Autologous Tumor Infiltrating Lymphocyte (TIL) Therapy in Patients with Advanced Melanoma: Evaluation of Impact of Prior Anti-PD-1 Therapy. J. Clin. Oncol. 2021, 39, 9505. [Google Scholar] [CrossRef]
- National Cancer Institute. Available online: https://www.cancer.gov/news-events/cancer-currents-blog/2024/fda-amtagvi-til-therapy-melanoma (accessed on 23 May 2024).
- Creelan, B.C.; Wang, C.; Teer, J.K.; Toloza, E.M.; Yao, J.; Kim, S.; Landin, A.M.; Mullinax, J.E.; Saller, J.J.; Saltos, A.N.; et al. Tumor-Infiltrating Lymphocyte Treatment for Anti-PD-1-Resistant Metastatic Lung Cancer: A Phase 1 Trial. Nat. Med. 2021, 27, 1410–1418. [Google Scholar] [CrossRef]
- National Cancer Institute. Available online: https://www.cancer.gov/news-events/press-releases/2022/personalized-immunotherapy-metastatic-breast-cancer (accessed on 23 May 2024).
- Tran, E.; Robbins, P.F.; Lu, Y.-C.; Prickett, T.D.; Gartner, J.J.; Jia, L.; Pasetto, A.; Zheng, Z.; Ray, S.; Groh, E.M.; et al. T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. N. Engl. J. Med. 2016, 375, 2255–2262. [Google Scholar] [CrossRef]
- Sharpe, M.; Mount, N. Genetically Modified T Cells in Cancer Therapy: Opportunities and Challenges. Dis. Model. Mech. 2015, 8, 337–350. [Google Scholar] [CrossRef]
- Kershaw, M.H.; Westwood, J.A.; Parker, L.L.; Wang, G.; Eshhar, Z.; Mavroukakis, S.A.; White, D.E.; Wunderlich, J.R.; Canevari, S.; Rogers-Freezer, L.; et al. A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer. Clin. Cancer Res. 2006, 12, 6106–6115. [Google Scholar] [CrossRef]
- Till, B.G.; Jensen, M.C.; Wang, J.; Chen, E.Y.; Wood, B.L.; Greisman, H.A.; Qian, X.; James, S.E.; Raubitschek, A.; Forman, S.J.; et al. Adoptive Immunotherapy for Indolent Non-Hodgkin Lymphoma and Mantle Cell Lymphoma Using Genetically Modified Autologous CD20-Specific T Cells. Blood 2008, 112, 2261–2271. [Google Scholar] [CrossRef] [PubMed]
- Besser, M.J.; Shapira-Frommer, R.; Itzhaki, O.; Treves, A.J.; Zippel, D.B.; Levy, D.; Kubi, A.; Shoshani, N.; Zikich, D.; Ohayon, Y.; et al. Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies. Clin. Cancer Res. 2013, 19, 4792–4800. [Google Scholar] [CrossRef] [PubMed]
- Park, J.R.; Digiusto, D.L.; Slovak, M.; Wright, C.; Naranjo, A.; Wagner, J.; Meechoovet, H.B.; Bautista, C.; Chang, W.-C.; Ostberg, J.R.; et al. Adoptive Transfer of Chimeric Antigen Receptor Re-Directed Cytolytic T Lymphocyte Clones in Patients with Neuroblastoma. Mol. Ther. 2007, 15, 825–833. [Google Scholar] [CrossRef] [PubMed]
- AstraZeneca Websites. Available online: https://www.astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/t-cell-receptor-therapies.html (accessed on 3 August 2024).
- Tsimberidou, A.-M.; Van Morris, K.; Vo, H.H.; Eck, S.; Lin, Y.-F.; Rivas, J.M.; Andersson, B.S. T-Cell Receptor-Based Therapy: An Innovative Therapeutic Approach for Solid Tumors. J. Hematol. Oncol. 2021, 14, 102. [Google Scholar] [CrossRef] [PubMed]
- Johnson, L.A.; Morgan, R.A.; Dudley, M.E.; Cassard, L.; Yang, J.C.; Hughes, M.S.; Kammula, U.S.; Royal, R.E.; Sherry, R.M.; Wunderlich, J.R.; et al. Gene Therapy with Human and Mouse T-Cell Receptors Mediates Cancer Regression and Targets Normal Tissues Expressing Cognate Antigen. Blood 2009, 114, 535–546. [Google Scholar] [CrossRef]
- Chodon, T.; Comin-Anduix, B.; Chmielowski, B.; Koya, R.C.; Wu, Z.; Auerbach, M.; Ng, C.; Avramis, E.; Seja, E.; Villanueva, A.; et al. Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma. Clin. Cancer Res. 2014, 20, 2457–2465. [Google Scholar] [CrossRef]
- Berset, M.; Cerottini, J.P.; Guggisberg, D.; Romero, P.; Burri, F.; Rimoldi, D.; Panizzon, R.G. Expression of Melan-A/MART-1 Antigen as a Prognostic Factor in Primary Cutaneous Melanoma. Int. J. Cancer 2001, 95, 73–77. [Google Scholar] [CrossRef]
- Fetsch, P.A.; Marincola, F.M.; Filie, A.; Hijazi, Y.M.; Kleiner, D.E.; Abati, A. Melanoma-Associated Antigen Recognized by T Cells (MART-1): The Advent of a Preferred Immunocytochemical Antibody for the Diagnosis of Metastatic Malignant Melanoma with Fine-Needle Aspiration. Cancer 1999, 87, 37–42. [Google Scholar] [CrossRef]
- Robbins, P.F.; Morgan, R.A.; Feldman, S.A.; Yang, J.C.; Sherry, R.M.; Dudley, M.E.; Wunderlich, J.R.; Nahvi, A.V.; Helman, L.J.; Mackall, C.L.; et al. Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1. J. Clin. Oncol. 2011, 29, 917–924. [Google Scholar] [CrossRef]
- Weon, J.L.; Potts, P.R. The MAGE Protein Family and Cancer. Curr. Opin. Cell Biol. 2015, 37, 1–8. [Google Scholar] [CrossRef]
- Mao, Z.; Lee, J.K. Expanding the Landscape of TCR Gene Therapy Targeting MAGE. Mol. Ther. Oncolytics 2023, 29, 59–60. [Google Scholar] [CrossRef] [PubMed]
- Dreno, B.; Thompson, J.F.; Smithers, B.M.; Santinami, M.; Jouary, T.; Gutzmer, R.; Levchenko, E.; Rutkowski, P.; Grob, J.-J.; Korovin, S.; et al. MAGE-A3 Immunotherapeutic as Adjuvant Therapy for Patients with Resected, MAGE-A3-Positive, Stage III Melanoma (DERMA): A Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial. Lancet Oncol. 2018, 19, 916–929. [Google Scholar] [CrossRef] [PubMed]
- Morgan, R.A.; Chinnasamy, N.; Abate-Daga, D.D.; Gros, A.; Robbins, P.F.; Zheng, Z.; Feldman, S.A.; Yang, J.C.; Sherry, R.M.; Phan, G.Q.; et al. Cancer Regression and Neurologic Toxicity Following Anti-MAGE-A3 TCR Gene Therapy. J. Immunother. 2013, 36, 133–151. [Google Scholar] [CrossRef] [PubMed]
- Schoenfeld, K.; Habermann, J.; Wendel, P.; Harwardt, J.; Ullrich, E.; Kolmar, H. T Cell Receptor-Directed Antibody-Drug Conjugates for the Treatment of T Cell-Derived Cancers. Mol. Ther. Oncol. 2024, 32, 200850. [Google Scholar] [CrossRef] [PubMed]
- Shafer, P.; Kelly, L.M.; Hoyos, V. Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects. Front. Immunol. 2022, 13, 835762. [Google Scholar] [CrossRef]
- Hurley, C.K.; Kempenich, J.; Wadsworth, K.; Sauter, J.; Hofmann, J.A.; Schefzyk, D.; Schmidt, A.H.; Galarza, P.; Cardozo, M.B.R.; Dudkiewicz, M.; et al. Common, Intermediate and Well-Documented HLA Alleles in World Populations: CIWD Version 3.0.0. HLA 2020, 95, 516–531. [Google Scholar] [CrossRef]
- Smithy, J.W.; Blouin, A.; Diamond, L.C.; Postow, M. Ensuring Equity in the Era of HLA-Restricted Cancer Therapeutics. J. Immunother. Cancer 2022, 10, e005600. [Google Scholar] [CrossRef]
- National Cancer Institute. Available online: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/car-t-cell-therapy (accessed on 3 August 2024).
- American Cancer Society. Available online: https://www.cancer.org/cancer/managing-cancer/treatment-types/immunotherapy/car-t-cell1.html (accessed on 4 August 2024).
- Feins, S.; Kong, W.; Williams, E.F.; Milone, M.C.; Fraietta, J.A. An Introduction to Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy for Human Cancer. Am. J. Hematol. 2019, 94, S3–S9. [Google Scholar] [CrossRef]
- Melenhorst, J.J.; Chen, G.M.; Wang, M.; Porter, D.L.; Chen, C.; Collins, M.A.; Gao, P.; Bandyopadhyay, S.; Sun, H.; Zhao, Z.; et al. Decade-Long Leukaemia Remissions with Persistence of CD4+ CAR T Cells. Nature 2022, 602, 503–509. [Google Scholar] [CrossRef]
- National Library of Medicine. Available online: https://clinicaltrials.gov/study/NCT01218867?cond=Melanoma&intr=CAR-T%20cells&aggFilters=results:with&rank=1&tab=results (accessed on 4 August 2024).
- Li, J.; Li, W.; Huang, K.; Zhang, Y.; Kupfer, G.; Zhao, Q. Chimeric Antigen Receptor T Cell (CAR-T) Immunotherapy for Solid Tumors: Lessons Learned and Strategies for Moving Forward. J. Hematol. Oncol. 2018, 11, 1–18. [Google Scholar] [CrossRef]
- National Cancer Institute. Available online: https://www.cancer.gov/about-cancer/treatment/research/car-t-cells (accessed on 4 August 2024).
- Soltantoyeh, T.; Akbari, B.; Karimi, A.; Mahmoodi Chalbatani, G.; Ghahri-Saremi, N.; Hadjati, J.; Hamblin, M.R.; Mirzaei, H.R. Chimeric Antigen Receptor (CAR) T Cell Therapy for Metastatic Melanoma: Challenges and Road Ahead. Cells 2021, 10, 1450. [Google Scholar] [CrossRef] [PubMed]
- Frey, N.; Porter, D. Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy. Biol Blood Marrow Transpl. 2019, 25, e123–e127. [Google Scholar] [CrossRef] [PubMed]
- Sermer, D.; Batlevi, C.; Palomba, M.L.; Shah, G.; Lin, R.J.; Perales, M.-A.; Scordo, M.; Dahi, P.; Pennisi, M.; Afuye, A.; et al. Outcomes in Patients with DLBCL Treated with Commercial CAR T Cells Compared with Alternate Therapies. Blood Adv. 2020, 4, 4669–4678. [Google Scholar] [CrossRef] [PubMed]
- Filin, I.Y.; Mayasin, Y.P.; Kharisova, C.B.; Gorodilova, A.V.; Kitaeva, K.V.; Chulpanova, D.S.; Solovyeva, V.V.; Rizvanov, A.A. Cell Immunotherapy against Melanoma: Clinical Trials Review. Int. J. Mol. Sci. 2023, 24, 2413. [Google Scholar] [CrossRef] [PubMed]
- Haanen, J.; Los, C.; Phan, G.Q.; Betof Warner, A. Adoptive Cell Therapy for Solid Tumors: Current Status in Melanoma and Next-Generation Therapies. Am. Soc. Clin. Oncol. Educ. Book. 2024, 44, e431608. [Google Scholar] [CrossRef]
- Malmberg, K.-J.; Carlsten, M.; Björklund, A.; Sohlberg, E.; Bryceson, Y.T.; Ljunggren, H.-G. Natural Killer Cell-Mediated Immunosurveillance of Human Cancer. Semin. Immunol. 2017, 31, 20–29. [Google Scholar] [CrossRef]
- Myers, J.A.; Miller, J.S. Exploring the NK Cell Platform for Cancer Immunotherapy. Nat. Rev. Clin. Oncol. 2021, 18, 85–100. [Google Scholar] [CrossRef]
- Liu, S.; Galat, V.; Galat4, Y.; Lee, Y.K.A.; Wainwright, D.; Wu, J. NK Cell-Based Cancer Immunotherapy: From Basic Biology to Clinical Development. J. Hematol. Oncol. 2021, 14, 7. [Google Scholar] [CrossRef]
- Li, Y.; Zhao, W.; Shen, Y.; Xu, Y.; Chen, S.; Pan, L. T Cell Receptor-Directed Bispecific T Cell Engager Targeting MHC-Linked NY-ESO-1 for Tumor Immunotherapy. Biomedicines 2024, 12, 776. [Google Scholar] [CrossRef]
- Bluemel, C.; Hausmann, S.; Fluhr, P.; Sriskandarajah, M.; Stallcup, W.B.; Baeuerle, P.A.; Kufer, P. Epitope Distance to the Target Cell Membrane and Antigen Size Determine the Potency of T Cell-Mediated Lysis by BiTE Antibodies Specific for a Large Melanoma Surface Antigen. Cancer Immunol. Immunother. 2010, 59, 1197–1209. [Google Scholar] [CrossRef]
- de Jong, G.; Bartels, L.; Kedde, M.; Verdegaal, E.M.E.; Gillissen, M.A.; Levie, S.E.; Cercel, M.G.; van Hal-van Veen, S.E.; Fatmawati, C.; van de Berg, D.; et al. Melanoma Cells Can Be Eliminated by Sialylated CD43 × CD3 Bispecific T Cell Engager Formats in Vitro and in Vivo. Cancer Immunol. Immunother. 2021, 70, 1569–1581. [Google Scholar] [CrossRef] [PubMed]
- Hua, G.; Carlson, D.; Starr, J.R. Tebentafusp-Tebn: A Novel Bispecific T-Cell Engager for Metastatic Uveal Melanoma. J. Adv. Pract. Oncol. 2022, 13, 717–723. [Google Scholar] [CrossRef] [PubMed]
- Zhou, S.; Liu, M.; Ren, F.; Meng, X.; Yu, J. The Landscape of Bispecific T Cell Engager in Cancer Treatment. Biomark. Res. 2021, 9, 38. [Google Scholar] [CrossRef] [PubMed]
- Einsele, H.; Borghaei, H.; Orlowski, R.Z.; Subklewe, M.; Roboz, G.J.; Zugmaier, G.; Kufer, P.; Iskander, K.; Kantarjian, H.M. The BiTE (Bispecific T-Cell Engager) Platform: Development and Future Potential of a Targeted Immuno-Oncology Therapy across Tumor Types. Cancer 2020, 126, 3192–3201. [Google Scholar] [CrossRef]
- Dreier, T.; Baeuerle, P.A.; Fichtner, I.; Grün, M.; Schlereth, B.; Lorenczewski, G.; Kufer, P.; Lutterbüse, R.; Riethmüller, G.; Gjorstrup, P.; et al. T Cell Costimulus-Independent and Very Efficacious Inhibition of Tumor Growth in Mice Bearing Subcutaneous or Leukemic Human B Cell Lymphoma Xenografts by a CD19-/CD3- Bispecific Single-Chain Antibody Construct. J. Immunol. 2003, 170, 4397–4402. [Google Scholar] [CrossRef] [PubMed]
- Simão, D.C.; Zarrabi, K.K.; Mendes, J.L.; Luz, R.; Garcia, J.A.; Kelly, W.K.; Barata, P.C. Bispecific T-Cell Engagers Therapies in Solid Tumors: Focusing on Prostate Cancer. Cancers 2023, 15, 1412. [Google Scholar] [CrossRef]
- Basnet, S.; Santos, J.M.; Quixabeira, D.C.A.; Clubb, J.H.A.; Grönberg-Vähä-Koskela, S.A.M.; Arias, V.; Pakola, S.; Kudling, T.V.; Heiniö, C.; Havunen, R.; et al. Oncolytic Adenovirus Coding for Bispecific T Cell Engager against Human MUC-1 Potentiates T Cell Response against Solid Tumors. Mol. Ther.-Oncolytics 2023, 28, 59–73. [Google Scholar] [CrossRef]
- Howlett, S.; Carter, T.J.; Shaw, H.M.; Nathan, P.D. Tebentafusp: A First-in-Class Treatment for Metastatic Uveal Melanoma. Ther. Adv. Med. Oncol. 2023, 15, 17588359231160140. [Google Scholar] [CrossRef]
- U.S. Food and Drug Administration. Available online: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tebentafusp-tebn-unresectable-or-metastatic-uveal-melanoma (accessed on 4 August 2024).
- Liu, L.; Chen, J. Therapeutic Antibodies for Precise Cancer Immunotherapy: Current and Future Perspectives. Med. Rev. 2021, 2, 555–569. [Google Scholar] [CrossRef]
- Dhillon, S. Tebentafusp: First Approval. Drugs 2022, 82, 703–710. [Google Scholar] [CrossRef]
- Hassel, J.C.; Piperno-Neumann, S.; Rutkowski, P.; Baurain, J.-F.; Schlaak, M.; Butler, M.O.; Sullivan, R.J.; Dummer, R.; Kirkwood, J.M.; Orloff, M.; et al. Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma. N. Engl. J. Med. 2023, 389, 2256–2266. [Google Scholar] [CrossRef] [PubMed]
- Szeligo, B.M.; Ivey, A.D.; Boone, B.A. Poor Response to Checkpoint Immunotherapy in Uveal Melanoma Highlights the Persistent Need for Innovative Regional Therapy Approaches to Manage Liver Metastases. Cancers 2021, 13, 3426. [Google Scholar] [CrossRef] [PubMed]
- Carvajal, R.D.; Butler, M.O.; Shoushtari, A.N.; Hassel, J.C.; Ikeguchi, A.; Hernandez-Aya, L.; Nathan, P.; Hamid, O.; Piulats, J.M.; Rioth, M.; et al. Clinical and Molecular Response to Tebentafusp in Previously Treated Patients with Metastatic Uveal Melanoma: A Phase 2 Trial. Nat. Med. 2022, 28, 2364–2373. [Google Scholar] [CrossRef] [PubMed]
- Edeline, J.; Houot, R.; Marabelle, A.; Alcantara, M. CAR-T Cells and BiTEs in Solid Tumors: Challenges and Perspectives. J. Hematol. Oncol. 2021, 14, 65. [Google Scholar] [CrossRef] [PubMed]
- de Miguel, M.; Umana, P.; Gomes de Morais, A.L.; Moreno, V.; Calvo, E. T-Cell–Engaging Therapy for Solid Tumors. Clin. Cancer Res. 2021, 27, 1595–1603. [Google Scholar] [CrossRef]
- Li, H.; Er Saw, P.; Song, E. Challenges and Strategies for Next-Generation Bispecific Antibody-Based Antitumor Therapeutics. Cell Mol. Immunol. 2020, 17, 451–461. [Google Scholar] [CrossRef]
- Braig, F.; Brandt, A.; Goebeler, M.; Tony, H.-P.; Kurze, A.-K.; Nollau, P.; Bumm, T.; Böttcher, S.; Bargou, R.C.; Binder, M. Resistance to Anti-CD19/CD3 BiTE in Acute Lymphoblastic Leukemia May Be Mediated by Disrupted CD19 Membrane Trafficking. Blood 2017, 129, 100–104. [Google Scholar] [CrossRef]
- Middelburg, J.; Kemper, K.; Engelberts, P.; Labrijn, A.F.; Schuurman, J.; van Hall, T. Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors. Cancers 2021, 13, 287. [Google Scholar] [CrossRef]
- Belmontes, B.; Sawant, D.V.; Zhong, W.; Tan, H.; Kaul, A.; Aeffner, F.; O’Brien, S.A.; Chun, M.; Noubade, R.; Eng, J.; et al. Immunotherapy Combinations Overcome Resistance to Bispecific T Cell Engager Treatment in T Cell-Cold Solid Tumors. Sci. Transl. Med. 2021, 13, eabd1524. [Google Scholar] [CrossRef]
- Wermke, M.; Alsdorf, W.; Araujo, D.; Chatterjee, M.; Hilf, N.; Holderried, T.A.W.; Jazaeri, A.A.; Kalra, M.; Mayer-Mokler, A.; Mendrzyk, R.; et al. Abstract PR018: IMA203 TCR-T Targeting PRAME Demonstrates Potent Anti-Tumor Activity in Patients with Different Types of Metastatic Solid Tumors. Mol. Cancer Ther. 2023, 22, PR018. [Google Scholar] [CrossRef]
- MJH Life Sciences. Available online: https://www.onclive.com/view/prame-shows-promise-as-a-treatment-avenue-in-melanoma-other-solid-tumors (accessed on 4 August 2024).
- VuMedi. Available online: http://www.vumedi.com/video/ascor-2024-summary-adopting-cutting-edge-cell-therapies-in-melanoma/?token=aa7e0eb1-3436-4547-b676-7c410139ce0a&link_data=eyJiZXRfbWFpbF9pdGVtX2lkIjoyMTEzNTczOTgsImJldF9tYWlsX2FjdGlvbiI6ImJjIn0%3A1sJ8Bv%3AFqYFDk4ueF1CzYcA_hyxp5yktsU_0YkAIjLBPyXkvg4 (accessed on 4 August 2024).
- Leonard-Murali, S.; Bhaskarla, C.; Yadav, G.S.; Maurya, S.K.; Galiveti, C.R.; Tobin, J.A.; Kann, R.J.; Ashwat, E.; Murphy, P.S.; Chakka, A.B.; et al. Uveal Melanoma Immunogenomics Predict Immunotherapy Resistance and Susceptibility. Nat. Commun. 2024, 15, 2863. [Google Scholar] [CrossRef] [PubMed]
- Tagliaferri, L.; Lancellotta, V.; Fionda, B.; Mangoni, M.; Casà, C.; Di Stefani, A.; Pagliara, M.M.; D’Aviero, A.; Schinzari, G.; Chiesa, S.; et al. Immunotherapy and Radiotherapy in Melanoma: A Multidisciplinary Comprehensive Review. Hum. Vaccines Immunother. 2022, 18, 1903827. [Google Scholar] [CrossRef] [PubMed]
- Demaria, S.; Formenti, S.C. The Abscopal Effect 67 Years Later: From a Side Story to Center Stage. Br. J. Radiol. 2020, 93, 20200042. [Google Scholar] [CrossRef] [PubMed]
Study Name (NCT Number) | Trial Stage | Therapeutic Approach | Enrollment | Disease/Stage |
---|---|---|---|---|
ACTME (NCT04330430) | Phase I/II (Active, Not Recruiting) | One cohort was given a combination of TILs and anti-PD-1 and the second was given TILs and anti-PD-1 with PEG-IFNa | 34 | Unresectable stage III–IV melanoma |
TIL (NCT02278887) | Phase III (Active, Not Recruiting) | TIL treatment vs Ipilimumab | 168 | Unresectable stage III–IV melanoma |
(NCT05176470) | Phase I (Active, Not Recruiting) | Neoadjuvant administration of TIL therapy with Pembrolizumab | 2 | Stage IIIB-D to stage IV melanoma |
(NCT01005745) | N/A (Active, Not Recruiting) | TILs with high dose IL-2 | 19 | Unresectable metastatic stage IV melanoma or stage III in-transit or regional nodal disease |
LN-144 (NCT02360579) | Phase II (Active, Not Recruiting) | Lifileucel | 178 | Unresectable or metastatic (Stage IIIc or IV) melanoma |
(NCT05470283) | Phase I (Active, Not Recruiting) | TILs engineered with membrane-bound IL15 plus acetazolamide | 21 | Unresectable stage III–IV melanoma |
mMEL (NCT03475134) | Phase I (Active, Not Recruiting) | TILs followed with or without nivolumab rescue | 18 | Unresectable stage IIIc–IV melanoma who have progressed on at least 1 standard first-line therapy |
TUNINTIL (NCT04217473) | Phase I (Active, Not Recruiting) | TNFalpha and IL-2 coding oncolytic adenovirus TILT-123 and TILs therapy | 17 | Previously treated refractory or recurrent stage 3–4 melanoma |
(NCT01659151) | Phase II (Active, Not Recruiting) | Vemurafenib with TILs therapy and high dose IL-2 | 17 | Unresectable metastatic stage IV melanoma or stage III in-transit or regional nodal disease |
(NCT00338377) | Phase II (Active, Not Recruiting) | TIL therapy with or without dendritic cell immunization | 1230 | Metastatic melanoma, uveal melanoma, or stage III in-transit or regional nodal disease |
(NCT01319565) | Phase II (Active, Not Recruiting) | TILs plus IL-2 following either a non-myeloablative Lymphocyte Depleting chemotherapy regimen alone or in combination with 12Gy total body irradiation | 102 | Metastatic melanoma with at least one lesion resectable for TIL generation |
(NCT01701674) | N/A | TILs plus IL-2 with Ipilimumab | 13 | Unresectable metastatic stage IV melanoma or stage III in-transit or regional nodal disease |
Study Name (NCT Number) | Trial Stage | Therapeutic Approach | Enrollment | Disease/Stage |
---|---|---|---|---|
(NCT02870244) | Phase I (Recruiting) | TIL 1383I TCR transduced T-cells | 18 | Advanced melanoma |
(NCT01586403) | Phase I (Active, not recruiting) | Two doses of autologous T-cell receptor transduced T-cells, administered along with IL-2 | 14 | Stage IV melanoma patients |
(NCT02650986) | Phase I/II (Active, not recruiting) | Genetically modified T-cells, with or without concurrent decitabine | 15 | Advanced melanoma, ovarian, fallopian, peritoneal, and synovial cancers |
(NCT02869217) | Phase I (Active, not recruiting) | TBI-1301 (TCR gene transduced autologous T lymphocyte) after cyclophosphamide and fludarabine pre-treatment | 22 | Solid tumors, including melanoma |
(NCT05296564) | Phase I/II (Recruiting) | HBI-0201 (TCR gene-engineered lymphocytes) | 3 | NY-ESO-1 expressing metastatic cancers, including stage IV melanoma |
(NCT03132922) | Phase I (Active, not recruiting) | MAGE-A4c1032 modified T-cell therapy | 71 | HLA-A2 positive participants with MAGE-A4 positive tumors, including melanoma |
(NCT04897321) | Phase I (Recruiting) | B7-H3-specific CAR T-cells, administered after lymphodepleting chemotherapy | 32 | B7-H3-positive tumors, including melanoma |
(NCT04483778) | Phase I (Active, not recruiting) | B7H3-specific CAR T-cells vs. B7H3-CD19-specific CAR T-cells vs. B7H3-CD19-specific CAR T-cells and pembrolizumab | 68 | Recurrent/refractory solid tumors, including melanoma in children and young adults |
(NCT04119024) | Phase I (Recruiting) | IL13Ralpha2 CAR T-cells | 18 | Stage IIIc or IV melanoma and other metastatic solid tumors |
(NCT04729543) | Phase I/II (Recruiting) | MAGE-C2/HLA-A2 TCR T-cells | 20 | Melanoma and head and neck cancer |
(NCT05415072) | Phase I/II (Recruiting) | Single-agent DYP688 | 124 | Metastatic uveal melanoma (MUM) and other melanomas with GNAQ/11 mutations |
(NCT05588453) | Phase I/II (Recruiting) | Natural killer cell therapy (UD TGFbetai NK cells) and temozolomide | 30 | Stage IV melanoma metastatic to the brain |
(NCT05629546) | Phase I (Not Yet Recruiting) | Autologous: Memory-like natural killer cells + nivolumab + relatilimab and Allogeneic: Memory-like natural killer cells + nivolumab + relatilimab | 33 | Advanced or metastatic melanoma that has progressed after at least 12 weeks or a minimum of 2 doses of treatment with a standard of care |
(NCT03420963) | Phase I (Recruiting) | Cyclophosphamide + etoposide + NK cells | 38 | Patients with relapsed or refractory solid tumors |
Study Name (NCT Number) | Trial Stage | Therapeutic Approach | Enrollment | Disease/Stage |
---|---|---|---|---|
(NCT05315258) | Phase II (Recruiting) | Tebentafusp | 850 | Cutaneous melanoma with molecular relapsed disease (MRD) and uveal melanoma with MRD |
(NCT05549297) | Phase II/III (Recruiting) | Tebentafusp as a monotherapy or in combination with pembrolizumab vs investigator’s choice | 460 | HLA-A*02:01-positive with previously treated non-ocular advanced melanoma |
TEBE-AM (NCT05549297) | Phase II/III (Recruiting) | Tebentafusp monotherapy in combination with pembrolizumab vs. standard of care | 460 | Previously treated advanced melanoma |
(NCT06070012) | Phase II (Not yet recruiting) | Tebentafusp | 44 | Previously untreated metastatic uveal melanoma with an integrated circulating tumor DNA biomarker |
(NCT06414590) | Phase II (Not yet recruiting) | Neoadjuvant tebentafusp | 19 | Locally Advanced, Unresectable Primary Uveal Melanoma |
(NCT03070392) | Phase II (Active, not recruiting) | Tebentafusp vs investigator’s choice (Dacarbazine, ipilimumab, or pembrolizumab) | 378 | Previously untreated advanced uveal melanoma |
(NCT02570308) | Phase I/II (Completed) | Tebentafusp | 146 | Advanced uveal melanoma with (HLA)-A*0201 positive |
PRISM-MEL-301 (NCT06112314) | Phase III (Recruiting) | IMC-F106C plus nivolumab vs. nivolumab and relatlimab vs. nivolumab alone | 680 | Previously untreated advanced melanoma |
ACTengine (NCT03686124) | Phase I (Recruiting) | IMA203/IMA203CD8 products, with or without combination nivolumab | 186 | Solid tumors that express PRAME |
(NCT05973487) | Phase I (Recruiting) | T-Plex, an autologous customized TCR therapy targeting specific peptide/HLA antigens | 100 | Locally advanced (unresectable) or metastatic solid tumors |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Nassief, G.; Anaeme, A.; Moussa, K.; Mansour, A.N.; Ansstas, G. Recent Advancements in Cell-Based Therapies in Melanoma. Int. J. Mol. Sci. 2024, 25, 9848. https://doi.org/10.3390/ijms25189848
Nassief G, Anaeme A, Moussa K, Mansour AN, Ansstas G. Recent Advancements in Cell-Based Therapies in Melanoma. International Journal of Molecular Sciences. 2024; 25(18):9848. https://doi.org/10.3390/ijms25189848
Chicago/Turabian StyleNassief, George, Angela Anaeme, Karen Moussa, Abdallah N. Mansour, and George Ansstas. 2024. "Recent Advancements in Cell-Based Therapies in Melanoma" International Journal of Molecular Sciences 25, no. 18: 9848. https://doi.org/10.3390/ijms25189848